mechanism of action of glp 1 agonists GLP-1 A Comprehensive Review of the

1 Introduction Metabolic dysfunction-associated steatotic liver disease (MASLD), formerly referred to as non-alcoholic fatty liver disease (NAFLD), has become the most prevalent chronic liver condition worldwide, affecting approximately one-third to nearly 40% of the adult population globally, with projections indicating an increase to over 55% by 2040 (1, 2)

Alcohol and lifestyle interactions Alcohol tolerance changes on GLP-1 medications are well-documented

Getting it at baseline provides a more complete picture of your metabolic health and helps quantify your response to GLP-1 treatment over time

Thats a slight bump, but not enough for a definitive cause-and-effect conclusion

Sica, G

The database includes all ADRs and medication errors documented by the FDA